This week in Barks & Bites: American pharmaceutical firm Johnson & Johnson announces $55 billion in U.S. factory investments to stay ahead of drug tariffs; the Court of Justice for the European Union reports a decrease in new IP cases in 2024 despite a 12% increase in overall litigation before the Court that year; the Federal Circuit issues precedential decisions confirming Hatch-Waxman litigation expenses as tax deductible, rejecting Abiomed’s bid to extend the doctrine of prosecution disclaimer, and confirming that the zone of natural expansion doctrine is purely defensive in trademark litigation; Mariah Carey wins summary judgment and a sanctions motion in a copyright case over “All I Want For Christmas is You”; the Patent Trial and Appeal Board issues an informative designation to a denial of inter partes review institution over inconsistent claim construction arguments; and the ITC says that Samsung Display did not prove a violation of Section 337 by active matrix OLED products imported into the U.S. by BOE Technology.
Recent Posts
- Trump Order Bars USPTO Patents Employees from POPA Membership But Will Not Yet Affect Telework
- CAFC Upholds Prosecution Laches Ruling Against Gil Hyatt
- Other Barks & Bites for Friday, August 29: CAFC Affirms Prosecution Laches Ruling Against Hyatt; Trump Admin Cancels USPTO CBA; Second Circuit Affirms Lack of Standing in Ripple Trademark Case
- CAFC Dodges Key Issues in Reversing District Court Finding for Google on Prosecution Laches
- CAFC Corrects PTAB’s Inventorship Analysis in First Appeal of AIA Derivation Proceeding